Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 210 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

REVIEW ARTICLE Table of Contents   
Year : 1995  |  Volume : 6  |  Issue : 3  |  Page : 298-303
Use of Erythropoietin in the Correction of Anemia in Pre-dialysis Patients

Saudi Center for Organ Transplantation, Riyadh, Saudi Arabia

Correspondence Address:
Faissal A.M Shaheen
Consultant Nephrologist and Director, Saudi Center for Organ Transplantation, P.O. Box 27049, Riyadh 11417
Saudi Arabia
Login to access the Email id

PMID: 18583739

Rights and Permissions

Anemia is a well recognized complication of chronic renal failure (CRF). Although the use of erythropoietin (EPO) in the treatment of anemia in patients on dialysis is well established, its use in pre-dialysis patients is less well recognized. The preferred route of administration of EPO in pre-dialysis patients is subcutaneous and it is indicated in any patient with CRF who is symptomatic of anemia. Studies have shown that EPO is effective in correcting anemia in these patients with a considerable improvement in quality­of-life scores. There have been no deleterious effects on blood pressure or rate of decline of renal function. However, these two indices should be monitored closely. Common causes of treatment failure include iron deficiency, blood loss and occult sepsis. The available evidence indicates that EPO therapy is safe and effective in the treatment of anemia in pre­dialysis patients.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded365    
    Comments [Add]    

Recommend this journal